Keep in mind the results from the ACV1 phase 2A trial are due this half alsoI would even suggest to metabolic that they change their name to reflect their wider drug portfolio
Market Close: The US Fed rate is one thing – but are FDI outflows bringing down a boring ASX in favour of Wall Street?